How stopping GLP-1 weight-loss drugs may raise risk of stroke or heart attack

South China Morning Post - Nov 20, 2026

Weight-loss drugs help people shed weight, protecting them from strokes and heart attacks. But many people gain weight again after stopping taking GLP-1 receptor agonists such as semaglutide (including trade names Ozempic and Wegovy) and tirzepatide (Mounjaro). For type 2 diabetes patients, the risk of serious cardiovascular events and death increases significantly once they stop treatment, according to a study published in The Lancet Regional Health Europe. About 80,000 people with type 2...

Read full article

More News

Obserworld

Delivering the latest news to the global audience with thorough research and in-depth interviews reporting on world news, latest trends, and inspirational stories.

NEWSLETTER